{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:16:18Z","timestamp":1788869778378,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In neovascular age-related macular degeneration (nAMD), persistent disease activity despite anti-VEGF therapy is common. Switching to faricimab may improve outcomes and extend treatment intervals in treatment-resistant patients, but long-term real-world data remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective, single-centre study, 43 eyes of 38 patients with treatment-resistant nAMD were switched to faricimab and followed for up to 24 months. Insufficient disease control was defined as inability to extend treatment intervals beyond 8 weeks under a treat-and-extend regimen. Outcomes included best-corrected visual acuity (BCVA), central subfield thickness (CST), pigment epithelial detachment (PED) height, fluid status, and treatment intervals. Longitudinal changes were analysed using mixed-effects models. Exploratory analyses of baseline and early response predictors were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean BCVA remained stable throughout follow-up, with no significant change from baseline at any time point (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). CST decreased significantly at all visits, ranging from \u2212\u200945.8\u00a0\u03bcm (95% CI\u2009\u2212\u200965.3\u00a0\u03bcm to \u2212\u200926.3\u00a0\u03bcm) at 1 month to \u2212\u200952.3\u00a0\u03bcm (95% CI\u2009\u2212\u200973.7\u00a0\u03bcm to \u2212\u200930.8\u00a0\u03bcm) at 24 months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). PED height decreased at 1 month (\u2212\u200919.0\u00a0\u03bcm; 95% CI\u2009\u2212\u200933.6\u00a0\u03bcm to \u2212\u20094.4\u00a0\u03bcm,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.011) and remained reduced from 12 to 24 months, ranging from \u2212\u200925.9\u00a0\u03bcm (95% CI\u2009\u2212\u200939.7\u00a0\u03bcm to \u2212\u200912.1\u00a0\u03bcm,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) to \u2212\u200949.1\u00a0\u03bcm (95% CI\u2009\u2212\u200965.1\u00a0\u03bcm to \u2212\u200933.0\u00a0\u03bcm,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Presence of subretinal fluid decreased significantly at all time points, with odds ratios (OR) ranging from 0.064 (95% CI 0.01 to 0.41,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004) at 1 month to 0.012 (95% CI 0.01 to 0.10,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) at 24 months, whereas intraretinal fluid showed a variable response, with a significant reduction observed at 3 months only (OR 0.204, 95% CI 0.05 to 0.79,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.021). The proportion of eyes with a dry macula increased from 0% at baseline to 23.1% at 12 months and 24.0% at 24 months. Treatment intervals extended from 5.9\u2009\u00b1\u20091.2 weeks before switch to 8.7\u2009\u00b1\u20092.6 weeks at 12 months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and 10.6\u2009\u00b1\u20093.0 weeks at 24 months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). No adverse events were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Switching to faricimab was associated with improved anatomical outcomes and extended treatment intervals while maintaining stable visual acuity, suggesting benefits primarily related to anatomical control and reduced treatment burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-026-00889-0","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:46:15Z","timestamp":1782211575000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world outcomes after switching to faricimab in previously treated neovascular age-related macular degeneration: longitudinal outcomes up to 24 months"],"prefix":"10.1186","volume":"12","author":[{"given":"Daniel","family":"Egger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Amesbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin E.","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Angermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian M.","family":"Waldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"issue":"2","key":"889_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106\u2013116. https:\/\/doi.org\/10.1016\/s2214-109x(13)70145-1. PubMed PMID: 25104651.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"889_CR2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.survophthal","volume":"69","author":"A Choi","year":"2024","unstructured":"Choi A, Nawash BS, Du K, Ong J, Chhablani J. Barriers to care in neovascular age-related macular degeneration: Current understanding, developments, and future directions. Surv Ophthalmol. 2024;69(1):160\u20134. https:\/\/doi.org\/10.1016\/j.survophthal.2023.09.001. PubMed PMID: 37716480.","journal-title":"Surv Ophthalmol"},{"issue":"9","key":"889_CR3","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.ophtha.2020.02.027","volume":"127","author":"S Kiss","year":"2020","unstructured":"Kiss S, Campbell J, Almony A, Shih V, Serbin M, LaPrise A, et al. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records. Ophthalmology. 2020;127(9):1179\u201388. https:\/\/doi.org\/10.1016\/j.ophtha.2020.02.027. PubMed PMID: 32345477.","journal-title":"Ophthalmology"},{"key":"889_CR4","doi-asserted-by":"publisher","first-page":"100906","DOI":"10.1016\/j.preteyeres.2020.100906","volume":"82","author":"PS Mettu","year":"2021","unstructured":"Mettu PS, Allingham MJ, Cousins SW. Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res. 2021;82:100906. https:\/\/doi.org\/10.1016\/j.preteyeres.2020.100906. PubMed PMID: 33022379; PubMed Central PMCID: PMC10368393.","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"889_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1001\/jamaophthalmol.2016.4820","volume":"135","author":"FL Ferris","year":"2017","unstructured":"Ferris FL, Maguire MG, Glassman AR, Ying G, shuang, Martin DF. Evaluating Effects of Switching Anti\u2013Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration and Diabetic Macular Edema. JAMA Ophthalmol. 2017;135(2):145. https:\/\/doi.org\/10.1001\/jamaophthalmol.2016.4820.","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"889_CR6","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1097\/IAE.0000000000003207","volume":"41","author":"A Eshtiaghi","year":"2021","unstructured":"Eshtiaghi A, Issa M, Popovic MM, Muni RH, Kertes PJ, Geographic atrophy incidence and progression after intravitreal injections, of anti-vascular endothelial growth factor agents for age-related macular degeneration. a meta-analysis. Retina. 2021;41(12):2424\u201335. https:\/\/doi.org\/10.1097\/IAE.0000000000003207. PubMed PMID: 34101693.","journal-title":"Retina"},{"key":"889_CR7","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ajo.2023.03.033","volume":"252","author":"F Romano","year":"2023","unstructured":"Romano F, Cozzi E, Airaldi M, Nassisi M, Viola F, Aretti A, et al. Ten-Year Incidence of Fibrosis and Risk Factors for Its Development in Neovascular Age-Related Macular Degeneration. Am J Ophthalmol. 2023;252:170\u201381. https:\/\/doi.org\/10.1016\/j.ajo.2023.03.033. PubMed PMID: 37030492.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"889_CR8","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","volume":"35","author":"AM Joussen","year":"2021","unstructured":"Joussen AM, Ricci F, Paris LP, Korn C, Quezada-Ruiz C, Zarbin M. Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data. Eye (Lond). 2021;35(5):1305\u201316. https:\/\/doi.org\/10.1038\/s41433-020-01377-x. PubMed PMID: 33564135; PubMed Central PMCID: PMC8182896.","journal-title":"Eye (Lond)"},{"issue":"8","key":"889_CR9","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, et al. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2. Ophthalmology. 2024;131(8):914\u201326. https:\/\/doi.org\/10.1016\/j.ophtha.2024.02.014. PubMed PMID: 38382813.","journal-title":"Ophthalmology"},{"issue":"15","key":"889_CR10","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1038\/s41433-025-03943-7","volume":"39","author":"E Jin","year":"2025","unstructured":"Jin E, Chan AC, Thomas GN. Efficacy of faricimab secondary to anti-vascular endothelial growth factor agents in patients with neovascular age-related macular degeneration: a systematic review and meta-analysis. Eye (Lond). 2025;39(15):2738\u201351. https:\/\/doi.org\/10.1038\/s41433-025-03943-7. PubMed PMID: 40836128; PubMed Central PMCID: PMC12494739.","journal-title":"Eye (Lond)"},{"key":"889_CR11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ajo.2025.08.034","volume":"280","author":"C Zhang","year":"2025","unstructured":"Zhang C, Aboukasm G, Lai DA, Leung N, Zhu D, Albini TA, et al. Clinical Efficacy of Switching to Faricimab in Treatment Resistant Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-analysis. Am J Ophthalmol. 2025;280:248\u201366. https:\/\/doi.org\/10.1016\/j.ajo.2025.08.034. PubMed PMID: 40849032.","journal-title":"Am J Ophthalmol"},{"key":"889_CR12","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.2147\/OPTH.S424315","volume":"17","author":"RB Rush","year":"2023","unstructured":"Rush RB. One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration. Volume. 2023;17:2201\u20138. https:\/\/doi.org\/10.2147\/OPTH.S424315.","journal-title":"Volume"},{"key":"889_CR13","doi-asserted-by":"publisher","unstructured":"Sim SY, Chalkiadaki E, Koutsocheras G, Nicholson L, Sivaprasad S, Patel PJ, et al. Real-world 1-Year outcomes of treatment-intensive neovascular age-related macular degeneration switched to faricimab. Ophthalmol Retina. 2025;9(1):22\u201330. https:\/\/doi.org\/10.1016\/j.oret.2024.07.020. PubMed PMID: 39084554.","DOI":"10.1016\/j.oret.2024.07.020"},{"key":"889_CR14","doi-asserted-by":"publisher","unstructured":"Cancian G, Paris A, Agliati L, Rizzato A, Clerici M, Volpe G, et al. One-year real-world outcomes of intravitreal faricimab for previously treated neovascular age-related macular degeneration. Ophthalmol Ther. 2024;13(11):2985\u201397. https:\/\/doi.org\/10.1007\/s40123-024-01036-4. PubMed PMID: 39340634; PubMed Central PMCID: PMC11493882.","DOI":"10.1007\/s40123-024-01036-4"},{"issue":"7","key":"889_CR15","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/s41433-025-03616-5","volume":"39","author":"IK Janmohamed","year":"2025","unstructured":"Janmohamed IK, Mushtaq A, Kabbani J, Harrow S, Nadarajasundaram A, Ata A, et al. 1-Year real-world outcomes of faricimab in previously treated neovascular age-related macular degeneration. Eye (Lond). 2025;39(7):1344\u20138. https:\/\/doi.org\/10.1038\/s41433-025-03616-5. PubMed PMID: 39863706; PubMed Central PMCID: PMC12044001.","journal-title":"Eye (Lond)"},{"key":"889_CR16","doi-asserted-by":"publisher","unstructured":"Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study\u2009\u2013\u20096 month results. Eye (Lond). 2023 May 12. https:\/\/doi.org\/10.1038\/s41433-023-02553-5. PubMed PMID: 37173428.","DOI":"10.1038\/s41433-023-02553-5"},{"issue":"1","key":"889_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.oret.2023.08.018","volume":"8","author":"A Szigiato","year":"2024","unstructured":"Szigiato A, Mohan N, Talcott KE, Mammo DA, Babiuch AS, Kaiser PK, et al. Short-Term Outcomes of Faricimab in Patients with Neovascular Age-Related Macular Degeneration on Prior Anti-VEGF Therapy. Ophthalmol Retina. 2024;8(1):10\u20137. https:\/\/doi.org\/10.1016\/j.oret.2023.08.018.","journal-title":"Ophthalmol Retina"},{"issue":"7","key":"889_CR18","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1007\/s00417-024-06421-0","volume":"262","author":"M Schneider","year":"2024","unstructured":"Schneider M, Bjerager J, Hodzic-Hadzibegovic D, Klefter ON, Subhi Y, Hajari J. Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2024;262(7):2153\u201362. https:\/\/doi.org\/10.1007\/s00417-024-06421-0.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"889_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1001\/jamaophthalmol.2022.1357","volume":"140","author":"NS Patil","year":"2022","unstructured":"Patil NS, Mihalache A, Dhoot AS, Popovic MM, Muni RH, Kertes PJ. Association Between Visual Acuity and Residual Retinal Fluid Following Intravitreal Anti\u2013Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-analysis. JAMA Ophthalmol. 2022;140(6):611. https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.1357.","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"889_CR20","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/aos.14786","volume":"99","author":"M Saenz-de-Viteri","year":"2021","unstructured":"Saenz-de-Viteri M, Recalde S, Fernandez-Robredo P, L\u00f3pez G\u00e1lvez MI, Arias Barquet L, Figueroa MS, et al. Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study. Acta Ophthalmol. 2021;99(8):861\u201370. https:\/\/doi.org\/10.1111\/aos.14786. PubMed PMID: 33720541.","journal-title":"Acta Ophthalmol"},{"key":"889_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2022.05.026","author":"DR Lally","year":"2022","unstructured":"Lally DR, Hill L, Amador-Patarroyo MJ. Subretinal Fluid Resolution and Visual Acuity in Patients with Neovascular Age-Related Macular Degeneration: A HARBOR Post Hoc Analysis. Ophthalmol Retina. 2022. https:\/\/doi.org\/10.1016\/j.oret.2022.05.026. PubMed PMID: 35654363. S2468-6530(22)00271-8.","journal-title":"Ophthalmol Retina"},{"issue":"9","key":"889_CR22","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.ophtha","volume":"127","author":"U Schmidt-Erfurth","year":"2020","unstructured":"Schmidt-Erfurth U, Vogl WD, Jampol LM, Bogunovi\u0107 H. Application of Automated Quantification of Fluid Volumes to Anti-VEGF Therapy of Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020;127(9):1211\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2020.03.010. PubMed PMID: 32327254.","journal-title":"Ophthalmology"},{"issue":"5","key":"889_CR23","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ophtha.2024.11.023","volume":"132","author":"CMG Cheung","year":"2025","unstructured":"Cheung CMG, Lim JI, Priglinger S, Querques G, Margaron P, Patel S, et al. Anatomic Outcomes with Faricimab vs Aflibercept in Head-to-Head Dosing Phase of the TENAYA\/LUCERNE Trials in Neovascular Age-related Macular Degeneration. Ophthalmology. 2025;132(5):519\u201326. https:\/\/doi.org\/10.1016\/j.ophtha.2024.11.023. PubMed PMID: 39617060.","journal-title":"Ophthalmology"},{"issue":"12","key":"889_CR24","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1038\/s41433-020-0799","volume":"34","author":"U Chakravarthy","year":"2020","unstructured":"Chakravarthy U, Pillai N, Syntosi A, Barclay L, Best C, Sagkriotis A. Association between visual acuity, lesion activity markers and retreatment decisions in neovascular age-related macular degeneration. Eye (Lond). 2020;34(12):2249\u201356. https:\/\/doi.org\/10.1038\/s41433-020-0799-y. PubMed PMID: 32066898; PubMed Central PMCID: PMC7784949.","journal-title":"Eye (Lond)"},{"issue":"3","key":"889_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00441-021-03514-8","volume":"387","author":"L Tenbrock","year":"2022","unstructured":"Tenbrock L, Wolf J, Boneva S, Schlecht A, Agostini H, Wieghofer P, et al. Subretinal fibrosis in neovascular age-related macular degeneration: current concepts, therapeutic avenues, and future perspectives. Cell Tissue Res. 2022;387(3):361\u201375. https:\/\/doi.org\/10.1007\/s00441-021-03514-8. PubMed PMID: 34477966; PubMed Central PMCID: PMC8975778.","journal-title":"Cell Tissue Res"},{"issue":"6","key":"889_CR26","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1177\/24741264241271649","volume":"8","author":"A Khodor","year":"2024","unstructured":"Khodor A, Choi S, Nanda T, Caranfa JT, Ruiz-Lozano RE, Desai SH, et al. Visual and anatomic responses in patients with neovascular age-related macular degeneration and a suboptimal response to Anti-VEGF therapy switched to faricimab. J VitreoRetinal Dis. 2024;8(6):643\u201350. https:\/\/doi.org\/10.1177\/24741264241271649.","journal-title":"J VitreoRetinal Dis"},{"issue":"3","key":"889_CR27","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/IAE.0000000000004322","volume":"45","author":"NR Ambati","year":"2025","unstructured":"Ambati NR, Leone A, Brill D, Sisk RA, Real-world long-term outcomes of intravitreal, faricimab in previously treated chronic neovascular age-related macular degeneration. Retina. 2025;45(3):446\u201353. https:\/\/doi.org\/10.1097\/IAE.0000000000004322. PubMed PMID: 39531583; PubMed Central PMCID: PMC11832180.","journal-title":"Retina"},{"issue":"1","key":"889_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaophthalmol.2019.4557","volume":"138","author":"K Mulligan","year":"2020","unstructured":"Mulligan K, Seabury SA, Dugel PU, Blim JF, Goldman DP, Humayun MS. Economic Value of Anti\u2013Vascular Endothelial Growth Factor Treatment for Patients With Wet Age-Related Macular Degeneration in the United States. JAMA Ophthalmol. 2020;138(1):40. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.4557.","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"889_CR29","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/jamaophthalmol.2024.4401","volume":"142","author":"N Paudel","year":"2024","unstructured":"Paudel N, Brady L, Stratieva P, Galvin O, Lui B, Van Den Brande I, et al. Economic Burden of Late-Stage Age-Related Macular Degeneration in Bulgaria, Germany, and the US. JAMA Ophthalmol. 2024;142(12):1123. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.4401.","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"889_CR30","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","volume":"128","author":"M Okada","year":"2021","unstructured":"Okada M, Mitchell P, Finger RP, Eldem B, Talks SJ, Hirst C, et al. Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration: A Mixed-Methods Systematic Review. Ophthalmology. 2021;128(2):234\u201347. https:\/\/doi.org\/10.1016\/j.ophtha.2020.07.060. PubMed PMID: 32763265; PubMed Central PMCID: PMC7403101.","journal-title":"Ophthalmology"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-026-00889-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00889-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00889-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:03:23Z","timestamp":1788869003000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-026-00889-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["889"],"URL":"https:\/\/doi.org\/10.1186\/s40942-026-00889-0","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study adhered to the tenets of the Declaration of Helsinki and received approval from the Ethics Committee of Lower Austria (GS3-EK-17\/063-2024).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent for publication of anonymized clinical data and images was obtained from all participants.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"D.E.: consultancy for Bayer. S.M.W.: consultancy for Bayer, Boehringer Ingelheim and Roche; research support from AbbVie, Bayer and Roche.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"118"}}